logo
  • We are open source synthetic biology.
    Using an open synthetic biology platform model, we rapidly prototype BactoBots and ViruBots. These applications make up our MicrobialBot portfolio. These applications are available to industry experts.

    Theses same platforms are available to responsible and capable researchers via Global SynBio and Open Therapeutics collaborative endeavors.
  • What We Do.
    Our open source synthetic biology platforms mimic natural selection. This biomimicry approach enables us to leverage millions of years of "prototyping" by natural selection. This speeds us forward in our areas of expertise: water, foods, fuels, chemicals, therapeutics, and materials.
  • Genetics Rights Management (GeRM™)
    Each MicrobialBot strain can be developed with its own unique genetics rights management (GeRM™) consumable key system. The GeRM™ system is similar to digital rights management, which is used by the software industry to protect its digital assets. GeRM™ enables us to ship our products via synthetic biology knowledge and consumable keys, instead of genetically modified organisms (GMO). In addition to protecting MicrobialBots against theft and environmental release, the GeRM™ system enables an economic development platform for creating home-grown synthetic biology industries.

    For more information about the GeRM™ value proposition, please visit our GeRM™ page.

Microbial Robotics is a global biotechnology firm. We rapidly prototype synthetic biology-based bacterial (BactoBots) and viral (ViruBots) technologies. These MicrobialBots products are provided to industrial customers. The MicrobialBots can perform functions such as bio-marker detection, kill cancer cells, produce chemicals or build materials, and can add value for the water, chemical, and pharmaceutical industries.

Our Open Therapeutics model and the Global SynBio network of scientists and industry professionals collaborate on open commercialization efforts to develop chemical, therapeutic, and water applications.

Proteome Antibiotics™ is a joint effort with Bacmine SL to develop an antibiotic discovery platform against pathogens including methicillin-resistant MRSA and multi-drug resistant tuberculosis (MDR-TB).

GeRM™ (patent pending) provides a competitive advantage in synthetic biology through enabling collaborative partnerships and recurring revenue models.